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Abstract
Background: In oromandibular dystonia (OMD) abnormal repetitive contractions of masticatory,
facial, and lingual muscles as well as the presence of orobuccolingual (OBL) dyskinesias may
interfere with the appropriate performance of tasks such as chewing and swallowing leading to
significant dysphagia and weight loss. We present here the clinical characteristics and treatment
variables of a series of patients that developed an OMD-associated eating dysfunction.
Methods: We present a series of patients diagnosed and followed-up at the Movement Disorders
Clinic of the Department of Neurology of University of Miami, Miller School of Medicine over a
10-year period. Patients were treated with botulinum toxin injections according to standard
methods.
Results: Five out of 32 (15.6%) OMD patients experienced symptoms of eating dysfunction
associated with OMD. Significant weight loss was reported in 3/5 patients (ranged for 13–15 lbs).
Two patients regained the lost weight after treatment and one was lost to follow-up. Tetrabenazine
in combination with other antidystonic medication and/or botulinum toxin injections provided
substantial benefit to the patients with dysphagia caused by OMD.
Conclusion: Dystonic eating dysfunction may occasionally complicate OMD leading to weight
loss. Its adequate characterization at the time of history taking and clinical examination should be
part of outcome measurements of the anti-dystonic treatment in clinical practice.
Background
In oromandibular dystonia (OMD) spasms of the masti-
catory, facial, and lingual muscles result in repetitive and
sometimes sustained jaw opening, closure, deviation, or
any combination of these as well as abnormal tongue
movements [1]. Although most cases are idiopathic, neu-
roleptic drugs can induce OMD [2,3]. OMD is very fre-
quently associated with orobuccolingual (OBL)
dyskinesias like facial grimacing, lip pursing and biting,
tongue protrusion, rotation and/or dyskinesias, platysma
contractions and bruxism [4]. A diagnosis of OMD carries
with it a significant impact on quality of life [5]. Its treat-
ment relies mainly on botulinum toxin type A injections
that have been proven beneficial for all its subtypes [4].
Due to the anatomical distribution of the muscles
affected, OMD and co-existing OBL dyskinesias are asso-
ciated with disturbed perioral, oral and lingual move-
ments that may interfere with the appropriate
performance of tasks such as chewing, swallowing or talk-
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ing, complicated with social embarrassment [6] and
sometimes eating disorders with weight loss [7]. We
present here the clinical characteristics and treatment var-
iables of a series of patients that developed an OMD-asso-
ciated eating dysfunction.
Methods
We performed a study of consecutive OMD patients fol-
lowed-up at the Movement Disorders Clinic of the
Department of Neurology of University of Miami, Miller
School of Medicine over a 10-year period. We identified
53 patients with primary and secondary OMD. We
excluded patients who were lost to follow up after initial
evaluation or had inconclusive charts (n = 21) (only
patients with at least 3 evaluations were included). Five
out of 32 (15.6%) OMD patients reported symptoms of
dystonic eating dysfunction. All OMD patients seen in our
practice are routinely asked a set of specific questions
about weight loss or eating difficulties associated with
OMD (have you experienced difficulties eating? Have you
experienced difficulties swallowing? Have you lost weight
after the onset of your disease?). All patients were exam-
ined and followed-up by the same physician (CS). Results
of treatment were analyzed using a global impression
scale (0 = no improvement; 1 = mild improvement; 2 =
moderate improvement; 3 = marked improvement). The
formulation and preparation of botulinum toxin type A
(BTX-A) (BOTOX®, Allergan Pharmaceuticals, Irvine, CA,
USA) was performed according to standard methods [8].
All patients that received BTX-A were injected bilaterally
under EMG guidance, using an Allergan® EMG needle. We
recorded the muscles injected and the dose each muscle
received. The mean dose of BTX-A for each patient was
determined by adding the units injected per visit divided
by the number of visits was used in the calculation of the
mean dose (in units) of BTX-A in each group. The initial
visit was not included since a lower than optimal dose of
botulinum toxin was used.
Case reports
Case 1
A 58-year-old male had been symptomatic for the preced-
ing 3 years with a chief complaint of involuntary move-
ments of jaw-opening triggered mainly by talking and/or
eating. His symptoms made his eating difficult requiring
him to bite down with effort in order to keep his mouth
from opening. He wore out his regular dentures and spe-
cial dentures had to be manufactured for him. Yelling
would ameliorate the involuntary movements. There was
no personal or family history of other neurological disor-
der and the patient denied any exposure to dopamine-
blocking drugs. He denied any weight loss, but admitted
to eating difficulty and social embracement due to his
jaw-opening OMD. His neurological examination was
otherwise unremarkable.
The patient was successfully treated with BTX-A injections
to his lateral pterygoids (75 units/side). After 9 sessions he
continues experiencing the same marked benefit and no
longer complains of eating difficulties.
Case 2
A 48-year-old female was initially evaluated for OMD of
one year evolution. She complained of intermittent invol-
untary movements of jaw-opening accompanied by
tongue thrusting. While eating her tongue would protrude
causing substantial eating and swallowing difficulties that
had lead to a 15 lbs weight loss (from 110 to 95 lbs). A
barium swallowing test at the time revealed her swallow-
ing function to be moderately impaired secondary to
decreased bolus preparation and decreased bolus propul-
sion without evidence of aspiration. After the unsuccessful
injections of BTX-A (4 sessions) to her lateral pterygoids
(50 u/side), she was placed on a regimen that included
tetrabenazine 75 mg/day, trihexyphenidyl 3 mg/day, and
lorazepam 4.5 mg/day with significant improvement of
her symptoms and gradual weight gain.
Case 3
A 32-year-old male presented with new-onset jaw-closure
spasms (jaw spasms with any kind of stimulus-able to
open his mouth only 1/4 inch). This process increased in
severity for three weeks, after which he could not take any
food in, except through a straw. For the ensuing two
months there was a gradual albeit limited improvement
where he was able to open his mouth 3/4 of an inch, and
from then on his condition had remained stationary. He
had to change to a soft, pureed diet. Chewing would result
in pain, particularly on the left mandibular area. His dys-
tonic disorder also interfered with his speech, forcing him
to keep his tongue behind the teeth to prevent from biting
it. The patient was successfully treated with BTX-A injec-
tions to his masseters (50 units/side). After 4 sessions he
continues to experience the same marked benefit and no
longer complains of eating difficulties.
Case 4
A 49-year-old female presented with a 2-year history of
jaw opening movements, which caused substantial drink-
ing difficulties. A year later these movements became con-
stant and were complicated with movements of the
tongue (tongue protrusion and dyskinesias) with conse-
quent impairment of fluid and food manipulation over-
lapping with chewing difficulties caused by her jaw-
opening OMD. The patient reported a 15 lbs weight loss
due to her condition (from 130 to 115 lbs).
She was subsequently placed on tetrabenazine (125 mg/
day) with moderate benefit in the frequency and intensity
of the jaw-opening movements. However, tongue protru-
sion and dyskinesias were not affected. The patient devel-Head & Face Medicine 2006, 2:47 http://www.head-face-med.com/content/2/1/47
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oped a hypokinetic extrapyramidal syndrome as a side
effect to tetrabenazine therapy but insisted on continuing
the drug (at a lowered dose of 75 mg/day) because of its
beneficial effects on her symptoms. Within about 6 moths
after the initiation of tetrabenazine the patient gained 10
lbs. In an effort to further control her symptoms the
patients had trials with clonazepam and gabapentin. A
combination of tetrabenazine (75 mg/day) and gabapen-
tin (300 mg/day) improved her symptoms by a reported
75%. She also received BTX-A injections to lateral ptery-
goid muscles (25 units/side) without benefit. Ten years
into her condition she still experiences substantial benefit
from her treatment.
Case 5
A 56-year-old female presented with a chief complaint of
involuntary jaw movements. The patient had a long (35-
year) history of migraines for which she had received a
number of treatments (triptans, beta-blockers and cal-
cium-channel blockers, anti-epileptics, anti-depressants,
clonazepam) with limited success. Her first trial with an
atypical neuroleptic (off-label use) was 2.5 years before
presentation when she had been started on ziprasidone
(80 mg/day) [9]. The patient experienced a moderate
decrease in the frequency and severity of her migraine
attacks, but 11 months later started noticing mild invol-
untary movements of the tongue. Ziprasidone was gradu-
ally discontinued. Within 2 weeks jaw-opening
involuntary movements were superimposed on the invol-
untary movements of the tongue. Gradually, her symp-
toms intensified, causing eating difficulties accompanied
by weight loss (from 123 to 110–13 lbs). She also experi-
enced occasional tongue and oral mucosa injuries. Her
neurological examination was otherwise unremarkable.
The patient had already received BTX-A injections on the
lateral pterygoids at least on two occasions without suc-
cess prior to visit to our clinic and declined repeat injec-
tions. She was lost to follow-up.
Results and discussion
We present here a series of 5 patients with eating dysfunc-
tion associated with OMD. The clinical and epidemiolog-
ical characteristics of our OMD cohort has been described
elsewhere [10]. The prevalence of eating dysfunction in
OMD in our cohort was 15.6%. The demographics, clini-
cal characteristic and treatment details of our patients are
presented in Table 1. Significant weight loss was reported
in 3 out of 5 patients with eating dysfunction and OMD.
Only patients with both OMD and OBL dyskinesias expe-
rienced weight loss. The weight loss ranged from 13–15
lbs (13.6% to 10.5% loss of initial body weight). Two
patients regained their lost weight after treatment and one
was lost to follow-up. Tetrabenazine in combination with
other antidystonic medication and/or BTX-A injections
provided substantial benefit to the patients with eating
dysfunction caused by OMD (tetrabenazine has been par-
ticularly effective in hyperkinetic movement disorders
[11]).
Table 1: Clinical characteristics and treatment outcomes of our patients
Patient Case 1 Case 2 Case 3 Case 4 Case 5
Type of OMD Jaw Opening Jaw Opening Jaw Closure Jaw Opening Jaw Opening
Etiology Idiopathic Idiopathic Idiopathic Idiopathic Tardive
Age 58 48 32 57 50
Gender Male Female Male Female Female
Duration 5y 1y 2y 10y 1y
Follow-up 3y 2y 1.5y 8y 1y
Other Dystonia No Blepharospasm No No No
Orofaciolingual involvement No Tongue protrusion No Tongue dyskinesias, 
bruxism
Facial grimacing, tongue 
dyskinesia, lip biting
Botulinum toxin/sessions Yes/9 Yes/4 Yes/4 Yes/1 Yes/2
Site(s) Lateral pterygoids 75 
u/side
Lateral pterygoids 50 u/side Masseters 50 
u/side
Lateral pterygoids 25 
u/side
Lateral. pterygoids
Total 150 100 100 50 N/A
Response (GIS) to Botulinum 
toxin A injections
Marked No Moderate No No
Duration of response 3 months ---- 3 months ----- ----
Antidystonic medications 
(response)
No trihexyphenidyl lorazepam, 
tetrabenazine, (marked)
No tetrabenazine, 
gabapentine (marked)
No
Weight loss No 15 lbs no 15 lbs 13 lbs
Weight gain after treatment ----- 15 lbs ----- 10 lbs N/APublish with BioMed Central    and   every 
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Various studies have shown that a range of swallowing
difficulties accompany focal cranio-cervical dystonias
such as spasmodic dysphonia and spasmodic torticollis
before treatment initiation [12-14]. Cervical dystonic con-
tractions leading to anatomical swallowing dysfunction
has been proposed as a possible mechanism [15,16]. This
interpretation may account for the dysphagia encountered
in at least some of our OMD patients. Other proposed,
previously reported mechanisms include excess duration
of muscle activity, frequent co-contraction, loss of rhyth-
micity during chewing, and abnormalities in the chewing
to swallowing transition phase [6]. These abnormalities,
similar in type to those encountered in other forms of
focal dystonia, may be the expression of an abnormal
motor control of basal ganglia over mastication-related
movement pattern generators of the brainstem [6].
Dysphagia has been also reported as a complication of
BTX-A therapy in OMD [8,17,18]. However, none of our
patients experienced further difficulty swallowing after
receiving BTX-A injections. In fact, improvement was
reported in 2 of the four of our patients who received this
treatment.
Our study has some inherent limitations commonly seen
in retrospective series. Documentation of all clinical and
treatment variables may not be complete. However, all
study patients have been evaluated and followed by the
same movement disorders specialist (CS). Hence the
impact of confounding factors such as inconsistencies in
the diagnosis, inaccurate history, inter-examiner differ-
ences, and under-documentation were reduced. Further-
more, there are no additional evaluations of masticatory
function (i.e. masticatory muscle EMG, jaw movement
recording) other than weight loss (which may be influ-
enced by many factors) and patient descriptions.
In summary, eating dysfunction was reported in 15.6% of
our OMD cases. Eating dysfunction was associated with
significant weight loss in three of our patients. Interest-
ingly, only patients with OBL dyskinesias experienced
weight loss. Additional difficulties included pain during
eating, social embarrassment and speech disturbance. A
measure of benefit was reported in the majority of our
patients with BTX-A injections and oral antidystonic med-
ications, especially tetrabenazine. Eating dysfunction
associated with OMD should be identified and adequately
characterized at the time of history taking and should be
part of outcome measurements of the anti-dystonic treat-
ment. Special attention has to be paid to patients with
OMD and OBL dyskinesias since in our cases they experi-
enced significant weight loss.
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